SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-073587
Filing Date
2023-12-28
Accepted
2023-12-28 16:10:07
Documents
13
Period of Report
2023-12-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20231222.htm   iXBRL 8-K 44309
2 EX-10.1 clsd-ex10_1.htm EX-10.1 29297
  Complete submission text file 0000950170-23-073587.txt   194329

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT clsd-20231222_pre.xml EX-101.PRE 9843
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT clsd-20231222.xsd EX-101.SCH 2469
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT clsd-20231222_lab.xml EX-101.LAB 13352
7 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20231222_htm.xml XML 4717
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

IRS No.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 231522818
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)